NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 126 filers reported holding NURIX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,299,831 | -1.6% | 930,914 | -12.6% | 0.01% | -8.3% |
| Q1 2023 | $9,455,761 | +89383.9% | 1,064,838 | +10.6% | 0.01% | -20.0% |
| Q4 2022 | $10,567 | -99.9% | 962,357 | -10.6% | 0.02% | -28.6% |
| Q3 2022 | $14,025,000 | -22.6% | 1,076,349 | -24.8% | 0.02% | -16.0% |
| Q2 2022 | $18,123,000 | -10.1% | 1,430,365 | -0.6% | 0.02% | +8.7% |
| Q1 2022 | $20,164,000 | -37.9% | 1,439,282 | +28.3% | 0.02% | -28.1% |
| Q4 2021 | $32,480,000 | +16.9% | 1,121,935 | +21.0% | 0.03% | +3.2% |
| Q3 2021 | $27,789,000 | – | 927,550 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |